Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFSNASDAQ:LQDANASDAQ:STIMNASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$24.11-2.4%$24.03$17.15▼$29.55$1.15B1.93377,572 shs589,838 shsLQDALiquidia$13.97+3.4%$14.29$8.26▼$16.81$1.19B0.23974,946 shs1.67 million shsSTIMNeuronetics$4.38-1.1%$4.25$0.52▼$5.92$288.27M1.97696,758 shs627,601 shsTNDMTandem Diabetes Care$16.85+0.5%$19.58$15.75▼$53.69$1.12B1.521.51 million shs1.71 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+0.98%+12.88%-4.82%-12.69%+38.35%LQDALiquidia-5.06%+0.15%-10.47%-5.26%+8.34%STIMNeuronetics-0.45%+8.85%+17.51%+38.44%+25.32%TNDMTandem Diabetes Care-4.01%+2.57%-13.02%-53.88%-54.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLFSBioLife Solutions2.5584 of 5 stars3.51.00.00.03.72.50.6LQDALiquidia2.8422 of 5 stars3.60.00.00.03.94.20.6STIMNeuronetics2.2063 of 5 stars3.32.00.00.02.81.70.6TNDMTandem Diabetes Care4.6602 of 5 stars4.34.00.04.93.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.00Buy$31.1729.27% UpsideLQDALiquidia 3.11Buy$26.6390.59% UpsideSTIMNeuronetics 2.67Moderate Buy$5.5025.57% UpsideTNDMTandem Diabetes Care 2.53Moderate Buy$43.81160.01% UpsideCurrent Analyst Ratings BreakdownLatest STIM, TNDM, BLFS, and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.004/10/2025TNDMTandem Diabetes CareMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$20.004/9/2025TNDMTandem Diabetes CareMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold3/20/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/20/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $34.003/20/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $25.003/20/2025LQDALiquidiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.003/6/2025BLFSBioLife SolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $30.003/5/2025STIMNeuroneticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/5/2025TNDMTandem Diabetes CareMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$45.00 ➝ $22.003/4/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $24.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$82.25M13.92N/AN/A$7.67 per share3.14LQDALiquidia$14.00M85.14N/AN/A$0.73 per share19.14STIMNeuronetics$74.89M3.85N/AN/A$1.18 per share3.71TNDMTandem Diabetes Care$940.20M1.19N/AN/A$4.81 per share3.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$66.43M-$0.50N/AN/AN/A-38.98%-6.61%-5.54%5/8/2025 (Estimated)LQDALiquidia-$78.50M-$1.67N/AN/AN/A-765.38%-163.21%-67.14%5/12/2025 (Estimated)STIMNeuronetics-$30.19M-$1.37N/AN/AN/A-50.09%-141.24%-32.77%5/6/2025 (Estimated)TNDMTandem Diabetes Care-$222.61M-$1.46N/AN/AN/A-14.84%-44.19%-11.99%4/30/2025 (Estimated)Latest STIM, TNDM, BLFS, and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025LQDALiquidia-$0.42N/AN/AN/A$3.23 millionN/A5/8/2025Q1 2025BLFSBioLife Solutions-$0.03N/AN/AN/A$22.22 millionN/A5/6/2025Q1 2025STIMNeuronetics-$0.13N/AN/AN/A$29.07 millionN/A4/30/2025Q1 2025TNDMTandem Diabetes Care-$0.60-$0.67-$0.07-$1.97$220.19 millionN/A3/19/2025Q4 2024LQDALiquidia-$0.38-$0.46-$0.08-$0.46$4.60 million$2.92 million3/3/2025Q4 2024BLFSBioLife Solutions-$0.06$0.26+$0.32$0.26$21.73 million$22.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife Solutions0.032.781.78LQDALiquidiaN/A6.336.33STIMNeuronetics4.903.162.87TNDMTandem Diabetes Care1.292.902.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%LQDALiquidia64.54%STIMNeuronetics53.59%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%LQDALiquidia30.10%STIMNeuronetics9.80%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.50 million45.37 millionOptionableLQDALiquidia5085.30 million59.16 millionOptionableSTIMNeuronetics18065.82 million27.37 millionOptionableTNDMTandem Diabetes Care2,60066.56 million64.23 millionOptionableSTIM, TNDM, BLFS, and LQDA HeadlinesRecent News About These CompaniesTandem Diabetes Care’s Strong Q1 Performance and Growth Drive Buy RatingApril 30 at 11:57 PM | tipranks.comTandem Diabetes Care, Inc. (TNDM) Q1 2025 Earnings Conference Call TranscriptApril 30 at 9:04 PM | seekingalpha.comTandem Diabetes Care (TNDM) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesApril 30 at 8:05 PM | zacks.comTandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue EstimatesApril 30 at 6:55 PM | zacks.comTandem Diabetes stock surges on revenue beat, strong guidanceApril 30 at 6:15 PM | investing.comTandem stock rises after hours on Q1 sales beatApril 30 at 6:15 PM | drugdeliverybusiness.comTandem Diabetes (NASDAQ:TNDM) Posts Better-Than-Expected Sales In Q1, Stock SoarsApril 30 at 6:15 PM | finance.yahoo.comTandem Diabetes Care Announces First Quarter 2025 Financial ResultsApril 30 at 4:05 PM | businesswire.comFirst Light Asset Management LLC Sells 733,190 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)April 30 at 8:13 AM | marketbeat.comInsights into Tandem Diabetes Care's Upcoming EarningsApril 29 at 7:07 PM | benzinga.comTandem Diabetes Care Q1 2025 Earnings PreviewApril 29 at 7:07 PM | msn.comTandem Diabetes (TNDM) Q1 Earnings Report Preview: What To Look ForApril 29 at 11:43 AM | msn.comWhat to Expect From These 3 MedTech Stocks This Earnings Season?April 29 at 10:15 AM | zacks.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Purchased by Gilder Gagnon Howe & Co. LLCApril 28 at 6:29 AM | marketbeat.comWells Fargo & Company MN Acquires 16,163 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)April 28 at 3:15 AM | marketbeat.comCanada Pension Plan Investment Board Purchases 15,100 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)April 27 at 4:33 AM | marketbeat.comRaymond James Financial Inc. Invests $5.89 Million in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)April 27 at 3:46 AM | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Invesco Ltd.April 27 at 3:45 AM | marketbeat.comOberweis Asset Management Inc. Has $18.25 Million Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)April 26, 2025 | marketbeat.comHood River Capital Management LLC Buys Shares of 1,278,047 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)April 25, 2025 | marketbeat.comTandem Diabetes Care (TNDM) to Release Earnings on WednesdayApril 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomBy Nathan Reiff | April 10, 2025View 3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomVertiv Crushes Q1 Estimates, Can the Stock Maintain Momentum?By Jeffrey Neal Johnson | April 28, 2025View Vertiv Crushes Q1 Estimates, Can the Stock Maintain Momentum?STIM, TNDM, BLFS, and LQDA Company DescriptionsBioLife Solutions NASDAQ:BLFS$24.11 -0.60 (-2.43%) As of 04:00 PM EasternBioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Liquidia NASDAQ:LQDA$13.97 +0.46 (+3.40%) As of 04:00 PM EasternLiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Neuronetics NASDAQ:STIM$4.38 -0.05 (-1.13%) As of 04:00 PM EasternNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Tandem Diabetes Care NASDAQ:TNDM$16.85 +0.08 (+0.48%) As of 04:00 PM EasternTandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
